Rubedo Life Sciences is a clinical-stage biopharmaceutical company developing a new class of selective small-molecule therapeutics that target pathologic senescent cells driving chronic, age-related diseases. Founded in 2018 by Marco Quarta, Julian Klein, and Mark Gallop, the company uses its ALEMBIC discovery platform to identify drug candidates that selectively eliminate or modulate disease-driving senescent cells implicated in inflammaging, fibrosis, and tissue degeneration. Its lead candidate, RLS-1496, is a first-in-class topical GPX4 modulator advancing through Phase 1 clinical studies for indications including plaque psoriasis, atopic dermatitis, skin aging, and actinic keratosis.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
20–50
Total Funding
$53.45M
3 rounds
Total raised $53.45M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series A
Date
April 22, 2024
Amount
$40M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| April 22, 2024 | Series A | $40M | — | Khosla Ventures, Ahren Innovation Capital |
| February 6, 2023 | CIRM Grant (IPF) | $1.45M | — | California Institute for Regenerative Medicine |
| December 3, 2020 | Seed | $12M | — | Khosla Ventures |
Frederick C. Beddingfield III
Chief Executive Officer and Board Director
Marco Quarta
Co-Founder and Chief Scientific Officer
Mark Gallop
Co-Founder and Chairman
Julian Klein
Co-Founder
Ali Siam
Chief Business Officer
Ofir Moreno
Senior Vice President, Discovery
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Unity Biotechnology
Pioneer in senolytic drug development targeting senescent cells in age-related diseases; founded out of Mayo Clinic and Buck Institute science. Was publicly traded (NASDAQ: UBX) before reportedly winding down operations.
Oisin Biotechnologies
Seattle-based biotech developing gene therapy-based senolytic platform that selectively destroys senescent and cancerous cells.
Senolytic Therapeutics
Barcelona/Boston-based biotech developing small-molecule senolytics targeting senescent cells in fibrotic and age-related disease.
FoxBio
Senolytics-focused biotech (Juvenescence portfolio) developing therapies that target senescent cells in age-related conditions.
Numeric Biotech
Early-stage senolytics company developing drug candidates aimed at clearing senescent cells driving aging pathology.
SIWA Therapeutics
Biotech developing antibody-based therapies targeting senescent and dysfunctional cells in cancer and age-related diseases.
No. Rubedo is a private company and does not have a public stock ticker or trade on a public stock exchange. Its shares are generally held by founders, employees, investors, and other private shareholders. Buyers and sellers may be able to transact in Rubedo shares through private secondary transactions, but any transaction depends on share availability, buyer and seller agreement, transfer restrictions, company approval rights, and any applicable right of first refusal. There is no guarantee that Rubedo will complete an IPO or other liquidity event.
Yes, it is sometimes possible to buy Rubedo shares pre-IPO through private secondary transactions. This depends on finding a willing seller, company approval, and satisfying any transfer restrictions or rights of first refusal.
Buyers interested in buying Rubedo shares on the secondary market typically do so through SetterVC and other secondary-market platforms, subject to eligibility requirements, share availability, transfer restrictions, and issuer approval. Buyers may need to satisfy sophistication, accreditation, institutional, platform, regulatory, or other eligibility requirements before participating. Once eligible, buyers may be able to view listings, make bids, and work with a licensed broker through the transaction process. Buyers should ensure they have appropriate legal and financial advisors guiding them before completing any transaction.
Rubedo's latest disclosed funding round was a Series A round in April 22, 2024. The round raised approximately $40M, with Khosla Ventures and Ahren Innovation Capital listed as disclosed lead or major investors. Primary funding rounds are different from secondary transactions: in a primary round, capital goes to the company, while in a secondary transaction, investors buy existing shares from current shareholders. Funding-round data reflects publicly reported or collected information and may be incomplete.
Rubedo has raised approximately $53.45M in disclosed funding across 3 rounds. These figures reflect primary capital raised by the company and do not include every possible secondary transaction, undisclosed round, debt facility, or private transfer. Reported funding totals can change as new rounds are announced or older round details are corrected. Eligible users can use SetterVC to track Rubedo's funding history alongside private-market activity where available.
Rubedo's disclosed investors include Khosla Ventures, Ahren Innovation Capital and California Institute for Regenerative Medicine. Investor lists are based on public reporting, company announcements, and collected funding-round data, and may be incomplete. Participation in a prior funding round does not mean those investors are currently buying or selling shares. On SetterVC, eligible users can review Rubedo's funding history, valuation history, and private-market activity alongside other venture-backed companies.
Rubedo's most-cited competitors include Unity Biotechnology, Oisin Biotechnologies, Senolytic Therapeutics, FoxBio, Numeric Biotech and SIWA Therapeutics. Investors often compare these companies by sector, product focus, valuation, funding raised, growth signals, investor base, and private-market activity.
Secondary-market demand for Rubedo shares can be affected by company performance, revenue growth, profitability, funding history, valuation, investor interest, sector momentum, public-market conditions, expected timing of a liquidity event, and the availability of shares for sale. Demand can also be affected by transfer restrictions, company approval rights, right of first refusal processes, limited information, and the price expectations of buyers and sellers. Strong demand does not guarantee strong pricing, liquidity, or investment returns. Weak demand does not necessarily reflect the company's long-term prospects. Demand signals should not be treated as a recommendation or prediction of investment performance. Buyers and sellers should treat demand signals as informational and conduct their own diligence before transacting.
Sellers often rely on intermediaries and platforms, such as SetterVC and other secondary-market platforms, to identify potential buyers. The exact process varies by company and transaction, but sellers often begin by confirming their ownership, desired price, transferability, and any company approval or notice requirements. If the seller agrees with a buyer on acceptable price and terms, the company may need to be notified through a share transfer notice or similar process. If a right of first refusal, company approval right, or other transfer restriction applies, the seller may need to wait until that process is completed. The parties may then execute a purchase and sale agreement, complete required transfer documentation, and close if all required conditions are satisfied. Sellers should always seek proper legal and financial advice before completing the transaction.
Yes, current and former Rubedo employees, early investors, and other existing shareholders may be able to sell vested shares before an IPO through a private secondary sale. This is not automatic; it depends on whether the shareholder has transferable shares, whether there is buyer demand, and whether the company's governing documents permit the transfer. Many companies require prior notice, company approval, or a right of first refusal before shares can be sold. Sellers should also seek proper legal and financial advice before proceeding.
A Rubedo secondary transaction usually involves an existing shareholder selling shares to a buyer before a public listing. The buyer and seller typically agree on price, number of shares, share class, and closing conditions. The seller may then need to notify Rubedo through a share transfer notice or similar process. If Rubedo or existing investors have approval rights, transfer restrictions, or a right of first refusal, those steps may need to be completed before the transfer can close. The parties typically enter into a purchase and sale agreement, complete any required transfer documentation, and close only if the necessary conditions are satisfied. Timing and certainty can vary by company and transaction.
In most private secondary transactions, parties commonly use a purchase and sale agreement that outlines price, terms, and conditions. They may also use share transfer documentation, often a stock transfer notice, share transfer notice, transfer instruction, or similar document, along with any required company approval or right of first refusal materials. Proof of ownership, such as a cap table entry, share certificate, brokerage statement, issuer confirmation, or administrator confirmation, may also be important. Buyers often request recent company financials, but private companies may limit disclosure. Since every deal varies, buyers and sellers should consult legal and financial advisors to understand which documents are needed.
Buying Rubedo shares pre-IPO is risky. Shares are illiquid, no IPO or liquidity event is guaranteed, valuations can change, transfers may require company approval, and private companies may provide limited financial disclosure. Be prepared for total loss. SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, verify information, and seek independent legal and investment advice before proceeding.
Private secondary shares are typically illiquid. Unlike public stocks, there is no active public market, so selling them can be difficult and time-consuming. Sales depend on finding a willing buyer and often require company approval. Investors should be prepared to hold the shares for an extended period, with no guarantee of a future sale. Always assess your need for liquidity before investing.
SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, including verifying ownership, transferability, legal structure, company approval, and assessing the company's prospects. SetterVC and Setter Capital do not provide advice on whether an investment is good, what price to pay, or what the best bid or ask is. SetterVC and Setter Capital may share documents in some circumstances, but it does not guarantee their accuracy or completeness. Due diligence is essential. Seek legal and investment advice as needed.
Before buying Rubedo shares, a buyer should try to review the share class, price per share, implied valuation, transfer restrictions, ROFR process, company approval rights, seller ownership evidence, recent financing or tender-offer information, available financial information, information rights, resale restrictions, tax considerations, and expected liquidity paths. Not all information may be available for a private company. Buyers should confirm available diligence, process details, and information needs with their own legal, tax, and investment advisers.
SPVs carry risks. Examples include the need to confirm the company allows SPV-based transfers, verify that the SPV truly owns the shares or interests it claims to own, and ensure it has not sold more interests than it holds. Due diligence is essential. Seek legal and investment advice as needed.
Forward contracts carry risks. Examples include the seller refusing to transfer the shares at the future date, even if the seller owns them, the seller going bankrupt with creditors claiming the shares, or the seller committing the same shares to multiple parties. Due diligence is essential. Seek legal and investment advice as needed.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.